India's Diabetes Care Market to Reach $60 Billion in Next 10 Years

In India, the diabetes care market in FY2021 was approximately $17 billion and it is expected to reach about $60 billion in the next 10 years, reveals a new report.

With 75 million diabetic patients, and another 200 million pre-diabetics, India is known as the diabetes capital of the world.

‘Diabetes, hypertension and cardiovascular disease are the top three chronic diseases in India and the market size is expected to grow nearly 3 times in the next 10 years.’

Poor lifestyle is the prime reason for the rapid increase in diabetes cases growth of the market, revealed the study done by Redcore, the research arm of Bengaluru-based research firm Redseer consulting.

According to the report, an average Indian spends Rs 11,000 annually on Type-2 diabetes care and Rs 3.5 lakh in a lifetime.

From Rs 6,000 annually in the early thirties, the cost increases exponentially to Rs 17,000 by the time they reach 60 years of age.

Further, the report showed that only 5 percent of the diabetic population falls in the average monthly income segment of Rs 80,000 or more, while 35 percent fall below Rs 20,000.

"Close to 95 percent of the diabetic population in India falls in the middle and low income category and has limited access to diabetes care. It is critical for India to identify a diabetes care solution which is affordable and comprehensive to make it a real success in the country," said Anuj Kumar, director, RedCore, in a statement.

New age tech-based innovations such as connected blood glucose monitoring devices and app based-doctor guidance and coaching are playing a significant role in transforming care in western world.

However, for India to see the adoption of these tech developments at a broad scale, accessibility and affordability will be the key.

The report also observed that within chronic diseases, diabetes (including prediabetes) has the highest prevalence, followed by cardiovascular disease and hypertension in India.

These top three chronic diseases represent a market size of about $35 billion in FY21, and are expected to grow nearly 3 times in the next 10 years, the report said.



Source: IANS